Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Exploratory Study to Identify Biomarkers Predictive of Clinical Response to Aflibercept in Patients With Metastatic Colorectal Cancer Who Have Failed First-Line Therapy

NCT02045030 is registered in ClinicalTrials.gov with CR-CSSS Champlain-Charles-Le Moyne as lead sponsor.

NCT NCT02045030
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02045030 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Exploratory Study to Identify Biomarkers Predictive of Clinical Response to Aflibercept in Patients With Metastatic Colorectal Cancer Who Have Failed First-Line Therapy
Lead sponsor
CR-CSSS Champlain-Charles-Le Moyne
Phase
Phase 2
Overall status
Terminated
Start date
January 31, 2014
Completion date
November 30, 2016
Enrollment
14 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic colorectal cancer